Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.26%
As of Friday, September 18, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.68%
As of Thursday, September 10, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 22.30%
As of Tuesday, September 08, Dyne Therapeutics, Inc.’s DYN share price has dipped by 22.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 15.96%
As of Tuesday, September 08, Dyne Therapeutics, Inc.’s DYN share price has dipped by 15.96%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.12%
As of Wednesday, July 22, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | DYN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,107.5 | $242.6 | 61% |
|
| Shares Out (Mil) | 165.5 | 54.0 | 73% |
|
| Institutional Ownership | 99.7% | 93.1% | 92% |
|
| Float (Mil) | 186.2 | 41.4 | 72% |
|
| Beta | 1.08 | 0.95 | 65% |
|
| Avg Daily Volume (000s) | 3,694 | 633 | 89% |
|
| Price Change (52-week) |
14.3% | 50.0% | 65% |
|
| Growth | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (49.7%) | (10.1%) | 7% |
|
| EPS (5yr) | 3.4% | 15.8% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (29.2%) | (15.7%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 15 | 13 | |
| Current EPS | ($0.888) | ($3.549) | ($3.335) | |
| Month Ago EPS | ($0.888) | ($3.549) | ($3.332) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.765) | ($3.091) | ($2.995) | |
| Year/Year Chg | (17.7%) | 2.2% | (27.5%) | |
| Financials | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($519) | ($44) | 3% |
|
| EPS (TTM) | ($3.349) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($478) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $192 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $214 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $4,209 | $177 | 60% |
|
| Valuation | DYN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.92 | 2.33 | 74% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DYN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (60.3%) | (47.6%) | 10% |
|
| ROE | (81.6%) | (54.9%) | 11% |
|
| Liabilities to Assets | 29.4% | 29.3% | 21% |
|
| F-Score | 1 | 3 | 1% |
|
Dyne Therapeutics, Inc. did not pass any screens on 10/9/2026.
